Onureg + Venetoclax
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Untreated Myelodysplastic Syndrome
Conditions
Untreated Myelodysplastic Syndrome
Trial Timeline
Dec 6, 2023 → Nov 1, 2028
NCT ID
NCT05782127About Onureg + Venetoclax
Onureg + Venetoclax is a phase 1/2 stage product being developed by AbbVie for Untreated Myelodysplastic Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT05782127. Target conditions include Untreated Myelodysplastic Syndrome.
What happened to similar drugs?
1 of 4 similar drugs in Untreated Myelodysplastic Syndrome were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05782127 | Phase 1/2 | Active |
Competing Products
15 competing products in Untreated Myelodysplastic Syndrome